In neonates, jaundice, caused by bilirubin buildup in tissues, is a key indicator of bilirubin excretion disorders.
A systematic review of 17 studies with 665 participants was conducted to evaluate the impact of clofibrate on reducing neonatal jaundice, with dosages ranging from 25 to 100 mg/kg.
Results showed that clofibrate significantly lowered bilirubin levels within 24 to 72 hours and also reduced hospitalization duration and associated costs.